June 1, 2009
Next Challenge Is How to Find Place in Actual Medical Practices Fixed-dose combination drugs are becoming a "boom." Micombi from Nippon Boehringer Ingelheim, which combines its angiotensin receptor blocker (ARB) telmisartan with the diuretic hydrochlorothiazide (HCT), was approved on April...read more